GlassScriptPhysician profile
Pei Liu
NPI 1003234550
$4,891.57
in general payments reported to CMS, 2019-2025
25 companies · $567 in 2025
The $567 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $768 · 2021: $1,171 · 2022: $449 · 2023: $696 · 2024: $611 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.65 | 2021-2025 | |
| Ucb, INC. | $1,105.02 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $755.73 | 2019-2025 | Ultomiris |
| Amgen INC. | $350.42 | 2019-2021 | |
| Biogen, INC. | $188.59 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $175.39 | 2019-2021 | |
| Neurelis, INC. | $152.33 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $152.15 | 2019-2021 | |
| Livanova USA, INC. | $147.63 | 2019-2020 | |
| Allergan, INC. | $102.92 | 2020 | |
| Mdd US Operations, LLC | $92.20 | 2019-2024 | Apokyn, Gocovri |
| Alnylam Pharmaceuticals INC. | $79.08 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $75.95 | 2021 | |
| Medline Industries LP | $55.33 | 2025 | |
| Medtronic, INC. | $41.08 | 2023 | Mazor X System, Signia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $34.16 | 2019-2020 | |
| Argenx US, INC. | $34.11 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Philips North America LLC | $32.43 | 2022 | |
| Eisai INC. | $23.67 | 2020 | |
| Amneal Pharmaceuticals LLC | $22.68 | 2020 | |
| Aquestive Therapeutics, INC. | $22.08 | 2020 | |
| Abbott Laboratories | $21.70 | 2025 | Infinity |
| Novartis Pharmaceuticals Corporation | $16.69 | 2021 | |
| Biomarin Pharmaceutical INC. | $16.09 | 2024 | Brineura |
| Resmed Corp | $15.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pei Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.